Published in Clin Diagn Lab Immunol on May 01, 1998
Mucosal FOXP3-expressing CD4+ CD25high regulatory T cells in Helicobacter pylori-infected patients. Infect Immun (2005) 2.33
Helicobacter pylori uses motility for initial colonization and to attain robust infection. Infect Immun (2002) 2.24
Helicobacter pylori-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun (2003) 2.19
Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination. J Clin Invest (1998) 1.47
Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect Immun (1998) 1.40
Helicobacter pylori-specific CD4+ T cells home to and accumulate in the human Helicobacter pylori-infected gastric mucosa. Infect Immun (2005) 1.12
Enhanced M1 macrophage polarization in human helicobacter pylori-associated atrophic gastritis and in vaccinated mice. PLoS One (2010) 1.05
Effects of oral vaccination and immunomodulation by cholera toxin on experimental Helicobacter pylori infection, reinfection, and gastritis. Infect Immun (2002) 1.00
Cholera caused by Vibrio cholerae O1 induces T-cell responses in the circulation. Infect Immun (2009) 0.99
HpaA is essential for Helicobacter pylori colonization in mice. Infect Immun (2006) 0.96
Role of local cytokines in increased gastric expression of the secretory component in Helicobacter pylori infection. Infect Immun (1999) 0.89
Immune response to H. pylori. World J Gastroenterol (2006) 0.86
Human gastric B cell responses can be induced by intestinal immunisation. Gut (2001) 0.86
Mucosal IgA & IL-1β in Helicobacter pylori Infection. Indian J Clin Biochem (2012) 0.85
Th1 and Th17 responses to Helicobacter pylori in Bangladeshi infants, children and adults. PLoS One (2014) 0.82
Galectin-3 Plays an Important Role in Innate Immunity to Gastric Infection by Helicobacter pylori. Infect Immun (2016) 0.82
CD4(+) regulatory T cells in gastric cancer mucosa are proliferating and express high levels of IL-10 but little TGF-β. Gastric Cancer (2016) 0.80
Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses. Clin Vaccine Immunol (2013) 0.78
Gastric cancer progression associated with local humoral immune responses. BMC Cancer (2015) 0.76
The rOmp22-HpaA fusion protein confers protective immunity against helicobacter pylori in mice. Curr Microbiol (2013) 0.76
Helicobacter pylori-specific immune responses of children: implications for future vaccination strategy. Clin Diagn Lab Immunol (2002) 0.76
The Relation between Helicobacter pylori Infection and Acute Bacterial Diarrhea in Children. Int J Pediatr (2014) 0.75
In vivo analysis of the viable microbiota and Helicobacter pylori transcriptome in gastric infection and early stages of carcinogenesis. Infect Immun (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem (1977) 36.95
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori. Association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem (1995) 12.61
Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet (1991) 6.73
Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology (1992) 4.63
Purification and characterization of urease from Helicobacter pylori. J Biol Chem (1990) 4.22
Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis (1984) 3.07
Identification, characterization, and spatial localization of two flagellin species in Helicobacter pylori flagella. J Bacteriol (1991) 2.94
Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol (1986) 2.77
Isolation and biochemical and molecular analyses of a species-specific protein antigen from the gastric pathogen Helicobacter pylori. J Bacteriol (1991) 2.69
The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis (1996) 2.66
Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis (1995) 1.97
Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol Suppl (1988) 1.93
Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol Suppl (1993) 1.86
Cloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori. J Bacteriol (1993) 1.85
Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology (1995) 1.77
Urease-associated heat shock protein of Helicobacter pylori. Infect Immun (1992) 1.71
Prevalence of CagA-bearing Helicobacter pylori strains detected by the anti-CagA assay in patients with peptic ulcer disease and in controls. Am J Gastroenterol (1996) 1.62
Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture. Infect Immun (1989) 1.48
Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect Immun (1998) 1.40
Identification of Helicobacter pylori by immunological dot blot method based on reaction of a species-specific monoclonal antibody with a surface-exposed protein. J Clin Microbiol (1995) 1.35
A simple, rapid, and highly reliable capsule-based 14C urea breath test for diagnosis of Helicobacter pylori infection. Scand J Gastroenterol (1995) 1.33
The putative neuraminyllactose-binding hemagglutinin HpaA of Helicobacter pylori CCUG 17874 is a lipoprotein. J Bacteriol (1995) 1.23
Antigenic characterization of Helicobacter pylori strains from different parts of the world. Clin Diagn Lab Immunol (1997) 1.21
Antigenicity of Helicobacter pylori lipopolysaccharides. J Clin Microbiol (1992) 1.19
Restriction fragment length polymorphism in the adhesin gene hpaA of Helicobacter pylori. Am J Gastroenterol (1995) 1.11
Quantification of conserved antigens in Helicobacter pylori during different culture conditions. Infect Immun (1997) 1.03
Safety of oral immunisation with recombinant urease in patients with Helicobacter pylori infection. Lancet (1996) 1.03
Isotypic analysis of specific antibody response in serum, saliva, gastric and rectal homogenates of Helicobacter pylori-infected patients. FEMS Immunol Med Microbiol (1995) 0.89
Local and systemic immune responses in humans against Helicobacter pylori antigens from homologous and heterologous strains. Microb Pathog (1997) 0.85
Flagellin gene profiling of Helicobacter pylori infecting symptomatic and asymptomatic individuals. Res Microbiol (1994) 0.82
Gastric output of IgA in man: relation to migrating motility complexes and sham feeding. Scand J Gastroenterol (1995) 0.81
Temperature-inducible outer membrane protein of Yersinia pseudotuberculosis and Yersinia enterocolitica is associated with the virulence plasmid. Infect Immun (1982) 6.63
Enzyme-linked immunosorbent assays for cholera serology. Infect Immun (1973) 6.10
Inhibition of phagocytosis in Yersinia pseudotuberculosis: a virulence plasmid-encoded ability involving the Yop2b protein. Infect Immun (1988) 4.61
Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol (1996) 4.47
Expression of the temperature-inducible outer membrane proteins of yersiniae. Infect Immun (1985) 4.36
Molecular cloning of the temperature-inducible outer membrane protein 1 of Yersinia pseudotuberculosis. Infect Immun (1984) 4.07
Analysis of the V antigen lcrGVH-yopBD operon of Yersinia pseudotuberculosis: evidence for a regulatory role of LcrH and LcrV. J Bacteriol (1991) 3.32
Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis (1984) 3.07
Virulence plasmid-associated autoagglutination in Yersinia spp. J Bacteriol (1984) 3.01
Synergistic protective effect in rabbits of immunization with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect Immun (1976) 2.92
Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis (1985) 2.78
Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease. J Clin Microbiol (1986) 2.77
Rapid GM1-enzyme-linked immunosorbent assay with visual reading for identification of Escherichia coli heat-labile enterotoxin. J Clin Microbiol (1983) 2.76
Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun (1998) 2.71
Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol (2000) 2.69
Monoclonal antibodies against Escherichia coli heat-stable toxin (STa) and their use in a diagnostic ST ganglioside GM1-enzyme-linked immunosorbent assay. J Clin Microbiol (1986) 2.65
Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol (1985) 2.49
Molecular cloning and expression of calcium-regulated, plasmid-coded proteins of Y. pseudotuberculosis. Microb Pathog (1987) 2.45
Development of improved cholera vaccine based on subunit toxoid. Nature (1977) 2.42
Transfer of the virulence plasmid of Yersinia pestis to Yersinia pseudotuberculosis. Infect Immun (1985) 2.24
The transfer of basic skills learned in a laparoscopic simulator to the operating room. Surg Endosc (2002) 2.21
Mechanisms of disease and immunity in cholera: a review. J Infect Dis (1977) 2.17
Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet (1994) 2.16
Intestinal antibody responses after immunisation with cholera B subunit. Lancet (1982) 2.13
Secretory immunoglobulin A and G antibodies prevent adhesion of Escherichia coli to human urinary tract epithelial cells. Infect Immun (1978) 2.13
Long-term results of a prospective randomized comparison of total fundic wrap (Nissen-Rossetti) or semifundoplication (Toupet) for gastro-oesophageal reflux. Br J Surg (1996) 2.11
Serologic differentiation between antitoxin responses to infection with Vibrio cholerae and enterotoxin-producing Escherichia coli. J Infect Dis (1983) 2.08
Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect Immun (1982) 2.08
Colonization factors of enterotoxigenic Escherichia coli isolated from children with diarrhea in Argentina. J Clin Microbiol (1991) 2.06
Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect Immun (1997) 2.01
Identification of a mannose-binding pilus on Vibrio cholerae El Tor. Microb Pathog (1991) 1.94
Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin Diagn Lab Immunol (1995) 1.89
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Presence of colonization factor antigens on fresh isolates of fecal Escherichia coli: a prospective study. J Infect Dis (1985) 1.87
Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination. Scand J Immunol (1977) 1.83
Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun (1991) 1.82
Antitoxic immunity in experimental cholera: protection, and serum and local antibody responses in rabbits after enteral and parenteral immunization. Infect Immun (1975) 1.82
Characterization of monoclonal antibodies against putative colonization factors of enterotoxigenic Escherichia coli and their use in an epidemiological study. J Clin Microbiol (1993) 1.81
Randomized clinical trial of laparoscopic gastric bypass versus laparoscopic duodenal switch for superobesity. Br J Surg (2010) 1.71
Evaluation of a ganglioside immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin. J Clin Microbiol (1979) 1.70
ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis (1989) 1.66
Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med (1983) 1.64
Quantitation of vibriocidal antibodies using agar plague techniques. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 1.63
Experimental studies on cholera immunization. 1. The response of neutralizing and vibriocidal antibodies in rabbits after immunization with culture filtrate material from V. cholerae. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.63
Local and systemic antibody responses and immunological memory in humans after immunization with cholera B subunit by different routes. Bull World Health Organ (1984) 1.62
Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralising activity and differentiation of human and porcine LTs and cholera toxin. Med Biol (1986) 1.61
Colonization factors of enterotoxigenic Escherichia coli isolated from children in north India. J Infect Dis (1996) 1.61
Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity. Int Arch Allergy Appl Immunol (1975) 1.56
Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine (1993) 1.54
Prospective cohort study of enterotoxigenic Escherichia coli infections in Argentinean children. J Clin Microbiol (1999) 1.50
Immune response to the mannose-sensitive hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139. Clin Diagn Lab Immunol (1997) 1.49
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine (1992) 1.49
Monoclonal antibodies against different epitopes on colonization factor antigen I of enterotoxin-producing Escherichia coli. J Clin Microbiol (1988) 1.48
Vibrio cholerae expresses cell surface antigens during intestinal infection which are not expressed during in vitro culture. Infect Immun (1989) 1.48
Induction of B cell responses in the stomach of Helicobacter pylori- infected subjects after oral cholera vaccination. J Clin Invest (1998) 1.47
Temporary percutaneous gastric electrical stimulation: a novel technique tested in patients with non-established indications for gastric electrical stimulation. Digestion (2010) 1.47
Monoclonal antibodies against the different subcomponents of colonization factor antigen II of enterotoxigenic Escherichia coli. J Clin Microbiol (1990) 1.47
Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera. Infect Immun (1994) 1.46
Mucosal immunity: implications for vaccine development. Immunobiology (1992) 1.45
Duodenal Helicobacter pylori infection differs in cagA genotype between asymptomatic subjects and patients with duodenal ulcers. Gastroenterology (1999) 1.44
Local and systemic antibody responses to naturally acquired enterotoxigenic Escherichia coli diarrhea in an endemic area. J Infect Dis (1986) 1.41
Epitope differences in toxin-coregulated pili produced by classical and El Tor Vibrio cholerae O1. Microb Pathog (1991) 1.41
A radial diffusion agar plaque technique for estimation of the avidity of bactericidal antibodies against Vibrio cholerae. Scand J Immunol (1972) 1.41
Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant. Am J Trop Med Hyg (1994) 1.40
Synergistic protective effect of antibodies against Escherichia coli enterotoxin and colonization factor antigens. Infect Immun (1982) 1.40
Receptor-like glycocompounds in human milk that inhibit classical and El Tor Vibrio cholerae cell adherence (hemagglutination). Infect Immun (1983) 1.40
Antibody-secreting cells in the stomachs of symptomatic and asymptomatic Helicobacter pylori-infected subjects. Infect Immun (1998) 1.40
Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine (1996) 1.39
Expression and detection of different biotype-associated cell-bound haemagglutinins of Vibrio cholerae O1. J Gen Microbiol (1989) 1.36
Identification of Helicobacter pylori by immunological dot blot method based on reaction of a species-specific monoclonal antibody with a surface-exposed protein. J Clin Microbiol (1995) 1.35
Phenotypic diversity of enterotoxigenic Escherichia coli strains from a community-based study of pediatric diarrhea in periurban Egypt. J Clin Microbiol (1999) 1.35
Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun (1992) 1.33
A simple, rapid, and highly reliable capsule-based 14C urea breath test for diagnosis of Helicobacter pylori infection. Scand J Gastroenterol (1995) 1.33
Immunoglobulin and specific-antibody synthesis in vitro by enteral and nonenteral lymphoid tissues after subcutaneous cholera immunization. Infect Immun (1977) 1.31
A new fimbrial putative colonization factor, PCFO20, in human enterotoxigenic Escherichia coli. Infect Immun (1993) 1.30
Comparative study of colony hybridization with synthetic oligonucleotide probes and enzyme-linked immunosorbent assay for identification of enterotoxigenic Escherichia coli. J Clin Microbiol (1988) 1.29
Analysis of incidence of infection with enterotoxigenic Escherichia coli in a prospective cohort study of infant diarrhea in Nicaragua. J Clin Microbiol (1997) 1.28
Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect Immun (1998) 1.28
Analysis of expression of toxin-coregulated pili in classical and El Tor Vibrio cholerae O1 in vitro and in vivo. Infect Immun (1992) 1.27
Intestinal and systemic immune responses in humans after oral immunization with a bivalent B subunit-O1/O139 whole cell cholera vaccine. Vaccine (1996) 1.27
Comparison of methods for detection of colonization factor antigens on enterotoxigenic Escherichia coli. J Clin Microbiol (1986) 1.27
Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine (1998) 1.26
Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults. J Infect Dis (1998) 1.26
Pneumatic dilatation or laparoscopic cardiomyotomy in the management of newly diagnosed idiopathic achalasia. Results of a randomized controlled trial. World J Surg (2007) 1.26
Nonimmunoglobulin fraction of human milk inhibits bacterial adhesion (hemagglutination) and enterotoxin binding of Escherichia coli and Vibrio cholerae. Infect Immun (1981) 1.26
Phenotypic and genotypic analysis of enterotoxigenic Escherichia coli in samples obtained from Egyptian children presenting to referral hospitals. J Clin Microbiol (2008) 1.24
Enterotoxins and adhesins of enterotoxigenic Escherichia coli: are they risk factors for acute diarrhea in the community? J Infect Dis (1990) 1.24
Randomized controlled trial of prophylactic chest physiotherapy in major abdominal surgery. Br J Surg (1997) 1.24
Campylobacter jejuni/coli and enterotoxigenic Escherichia coli (ETEC) in faeces from children and adults in Tanzania. Scand J Infect Dis (1995) 1.23
Cholera and the immune response. Prog Allergy (1983) 1.22
Experimental enterotoxin-induced Escherichia coli diarrhea and protection induced by previous infection with bacteria of the same adhesin or enterotoxin type. Infect Immun (1985) 1.21
Genetic fusion of a non-toxic heat-stable enterotoxin-related decapeptide antigen to cholera toxin B-subunit. FEBS Lett (1988) 1.21
An oral B subunit: whole cell vaccine against cholera. Vaccine (1992) 1.20
Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children. PRIDE Study Group. J Infect Dis (1999) 1.20
Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis (1993) 1.20